肝硬化合并门静脉血栓形成抗凝治疗的有效性及安全性的荟萃分析

发布时间：2018-07-11 17:54

本文选题：肝硬化 + 门静脉血栓　；参考：《山西医科大学》2017年硕士论文

【摘要】：目的:系统评价抗凝治疗门静脉血栓形成在肝硬化患者中的有效性及安全性。方法:计算机检索Cochrane Library、PubMed、EMBASE、Web of Science、ScienceDirect及中国知网(CNKI)、维普数据库和万方数据库中有关肝硬化伴门静脉血栓形成接受抗凝治疗的临床对照研究,对检索到的文献进行筛选、质量评价及资料数据提取;采用Review Manager 5.3.5软件对数据进行Meta分析。计数资料采用比值比(odds ratio,OR)及95%可信区间(95%confidence interval,95%CI)。结果:共纳入7篇文献,均为临床对照研究,合计343例肝硬化并发有门静脉形成的患者,其中抗凝治疗187例,未抗凝治疗156例。荟萃分析结果显示:在肝硬化并门脉血栓的患者中,门静脉的再通率情况抗凝组高于对照组[OR=7.31,95%CI(4.15,12.87),Z=6.89,P0.00001],出血等不良事件发生率在抗凝组与对照组间差异无统计学意义[OR=0.36,95%CI(0.07,1.91),Z=1.20,P=0.23]。结论:抗凝治疗肝硬化患者的门脉血栓是有效的,但其安全性方面仍尚待进一步研究。
[Abstract]:Objective: to evaluate the efficacy and safety of anticoagulant therapy for portal vein thrombosis in cirrhotic patients. Methods: the clinical controlled studies on anticoagulant therapy of cirrhotic patients with portal vein thrombosis were searched on the Cochrane Library PubMeden Web of Science Science Direct and CNKI, Weip database and Wanfang database. Quality evaluation and data extraction; Meta-analysis of data by Review Manager 5.3.5 software. Odds ratioor and 95% CI were used. Results: a total of 7 articles were included in this study. 343 patients with cirrhosis complicated with portal vein formation were included in this study. 187 cases were treated with anticoagulant therapy and 156 cases were treated with no anticoagulant therapy. The results of meta-analysis showed that the recanalization rate of portal vein in patients with cirrhosis and portal vein thrombosis was higher than that in the control group [OR7.31 卤95CI (4.15 卤12.87)]. The incidence of adverse events such as hemorrhage had no significant difference between the anticoagulant group and the control group [OR0.36 9595 CI (0.071.91) CI (0.071.91)]. Conclusion: anticoagulant therapy for portal thrombosis in patients with liver cirrhosis is effective, but its safety remains to be further studied.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R575.2

【参考文献】